Latest Regulatory Approvals News

CSL Limited has announced an ordinary dividend of USD 1.30 per share for the six months ending December 2025, payable in April 2026 with multi-currency options for shareholders.

Elanor Investors Group has secured securityholder approval for a $125 million recapitalisation with Rockworth Capital Partners and the acquisition of Firmus Capital, marking a pivotal step in stabilising its balance sheet and positioning for growth.

Island Pharmaceuticals has confirmed the material significance of recent FDA feedback on its Galidesivir development pathway and addressed ASX queries on disclosure timing and capital raising activities.

Godolphin Resources has identified a significant new induced polarisation anomaly 1,000 metres from its Lewis Ponds deposit, alongside high-grade gold, zinc, and copper surface samples, setting the stage for a targeted drilling campaign in March 2026.

NexGen Energy is advancing through the final Canadian Nuclear Safety Commission hearing for its Rook I uranium project, buoyed by strong Indigenous community support and over a decade of environmental and social groundwork.

Boab Metals has obtained the last major environmental approval needed to kickstart construction at its Sorby Hills Silver-Lead-Zinc Project in Western Australia, setting the stage for production in 2027.

PMET Resources has announced a significant capital raise of up to C$130 million through a public offering and a flow-through private placement to advance its Shaakichiuwaanaan critical minerals project in Quebec. The funds will support updated feasibility studies and exploration, aiming to de-risk the path to a Final Investment Decision.

Talga Group has lodged a detailed prospectus for issuing attaching and piggyback options to recent Placement and Share Purchase Plan participants, potentially raising up to A$32.7 million upon exercise. The move supports its battery anode production scale-up and international expansion plans.

US Masters Residential Property Group aims to divest its entire portfolio by the end of 2026, signalling an end to its operations. The group will prepare 2025 financials on a non-going concern basis, reflecting this strategic wind-down.

Sky Metals has revealed significant new tin mineralisation extensions at its Tallebung project in NSW, confirmed by recent drilling and surface sampling. The company is advancing a major resource update, signalling strong growth potential.

Orion Minerals has locked in a US$250 million prepayment facility with Glencore to fund key developments at its Prieska Copper Zinc Project, marking a pivotal step toward production in South Africa.

Paradigm Biopharmaceuticals has entered a binding agreement with AVet Health to co-develop and license a novel oral therapy for veterinary osteoarthritis in Australia and New Zealand, unlocking new market potential while advancing its human clinical trials.